Skip Navigation LinksHome > December 2009 - Volume 32 - Issue 6 > Angiosarcoma of the Breast: A Rare Clinicopathological Entit...
American Journal of Clinical Oncology:
doi: 10.1097/COC.0b013e3181967f09
Original Article: Breast

Angiosarcoma of the Breast: A Rare Clinicopathological Entity

Biswas, Tithi MD*; Tang, Ping MD†; Muhs, Ann BA*; Ling, Marilyn MD*

Collapse Box


Objectives: Angiosarcoma is a rare subtype of sarcoma that usually arises after radiation therapy for primary breast cancer. Primary sarcomas of the breast are rare entities and account for less than 1% of all malignant breast neoplasms. We examine our institutional experience with angiosarcomas of the breast that were diagnosed and treated between 1996 and 2007.

Methods: To conduct a retrospective review, all female patients with a diagnosis of angiosarcoma of the breast were identified from our pathology database. Their hospital records were retrieved to gather information on treatment, tumor response, failure, and survival.

Results: A total of 8 patients were identified who had a histologically confirmed diagnosis of angiosarcoma of the breast. Median age was 70.3 years at diagnosis (range, 35.6–85.7 years). Seven (87%) patients had a history of prior radiation to the breast, whereas 1 (13%) had primary angiosarcoma. The median overall survival was 37.4 months (8.7–92.8 months) and relapse-free survival was 17.9 months (2.5–69.4 months).

Conclusions: Even though angiosarcomas are rare neoplasms, they are increasingly recognized as the result of more breast-conserving therapy. High clinical suspicion and MRI may contribute to early diagnosis but a biopsy is always necessary to confirm it. These tumors tend to behave aggressively and require a multidisciplinary approach to improve the outcome.

© 2009 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.